focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: 0.00 (0.00%)
Spread: 0.20 (11.111%)
Open: 1.90
High: 1.90
Low: 1.90
Prev. Close: 1.90
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks head higher as pound tops USD1.28 again

Fri, 16th Jun 2023 08:47

(Alliance News) - Stock prices in London opened higher on Friday, taking their cue from Asian and US equities, while investors weighed recent interest rate decisions.

The FTSE 100 index opened up 25.03 points, 0.3%, at 7,653.27. The FTSE 250 was up 47.47 points, 0.3%, at 19,086.88, and the AIM All-Share was up 2.50 points, 0.3%, at 794.06.

The Cboe UK 100 was up 0.3% at 763.65, the Cboe UK 250 was 0.2% at 16,654.07, and the Cboe Small Companies was up 0.2% at 13,923.00.

"The UK market is on its own streak this week, with yesterday marking the fourth consecutive session of gains as investors try and make heads or tails of mixed data from around the globe," said Hargreaves Lansdown's Matt Britzman.

In a week dominated by central bank decisions elsewhere, market attention is shifting to the BoE's own decision next Thursday. The pound continued its upward trajectory, as sticky inflation data, combined with strong employment and economic growth prints, set the stage for the BoE to continue its rate-hiking cycle.

Sterling was quoted at USD1.2788 early Friday, rising from USD1.2759 at the London equities close on Thursday. The pound had risen past the USD1.28 mark shortly after Friday's equity market open in London. Sterling traded at its best level since April 2022.

The latest central bank decision came from the Bank of Japan, which said it would maintain its long-standing, ultra-loose monetary policy as it looks to boost economic growth.

It left its negative interest rate in place and did not adjust the band in which rates for 10-year government bonds fluctuate, a scheme known as yield curve control

Against the yen, the dollar was quoted at JPY140.74, up versus JPY140.52.

Officials had been widely expected to keep policies unchanged after the second two-day meeting chaired by new Governor Kazuo Ueda.

The central bank has gone against the grain as its global peers hike interest rates to tackle inflation, pushing down the value of the yen against the dollar.

The Nikkei 225 index in Tokyo closed up 0.7%, consolidating recent highs on the back of the weak yen.

"The overbought market conditions, and the idea that Japan will, one day in our lifetime, normalize rates could lead to some profit taking, but it's also true that companies in geopolitically sensitive sectors like defence and semiconductors have been major drivers of the rally this year, and there is no reason for that appetite to change when the geopolitical landscape remains this tense," said Swissquote Bank's Ipek Ozkardeskaya.

In China, the Shanghai Composite was up 0.3%, while the Hang Seng index in Hong Kong was up 1.4%. The S&P/ASX 200 in Sydney closed up 1.1%.

Asian equities got a boost after China's central bank cut a key interest rate and injected USD33 billion into financial markets on Thursday. This comes after recent data suggested the country's economic recovery was flagging.

Gold was quoted at USD1,961.01 an ounce early Friday, up from USD1,955.88 on Thursday. Brent oil fetched USD75.75 a barrel, rising from USD74.81.

In European equities on Friday, the CAC 40 in Paris was up 0.1%, while the DAX 40 in Frankfurt was flat.

The euro traded at USD1.0952 early Friday, higher than USD1.0930 late Thursday.

The ECB lifted interest rates in the eurozone by 25 basis points, as expected, on Thursday. The Frankfurt-based central bank acknowledged in its statement on Thursday that inflation has been coming down, but is nonetheless projected to remain "too high for too long".

ECB President Christine Lagarde said a pause was not even an option for the ECB. Her words suggest a hike in July is all but assured, and that the September meeting is also a live one.

Stocks on Wall Street rallied on Thursday, despite hawkish rhetoric from the US Federal Reserve, with the Dow Jones Industrial Average up 1.3%, while the S&P 500 and the Nasdaq Composite both rose 1.2%.

The Federal Reserve left interest rates unchanged on Wednesday but signalled further increases were on the way before the end of the year. But with US two-year Treasury yields narrowing to around 4.65% late Thursday, from 4.69% ahead of the Fed decision on Wednesday, there is a sign some investors are not buying the central bank's hawkish narrative.

In London's FTSE 100 index, Tesco fell 1.1%

The company said it was seeing signs that inflation is easing in the grocery market, and the supermarket chain backed annual guidance as it kicked off its financial year with a sales hike.

Tesco said revenue in the 13 weeks to May 27, its first quarter, rose 9.4% to GBP15.17 billion. The measure excludes both VAT and fuel, but includes Tesco Bank.

Looking ahead, Tesco said it still expects retail free cash flow within its GBP1.4 billion to GBP1.8 billion target range. At best, this would be a 16% fall from GBP2.13 billion in financial 2023.

It still expects a "broadly flat level" of retail adjusted operating profit. Retail adjusted operating profit fell 6.1% to GBP2.49 billion from GBP2.65 billion in financial 2023.

"Tesco is managing the weakening consumer landscape about as well as possible. That's being helped by the group's enormous scale... The mature, deeply rooted, nature of its relationships has been a key tool in helping to keep prices down," said HL's Aarin Chiekrie.

Meanwhile, among mid-caps, Travis Perkins slumped 7.6%.

The builders' merchant said it had delivered a "resilient" performance in the first quarter of 2023, but it has not seen the anticipated easing of market conditions in the second quarter to date.

"Volumes in both the new build housing and private domestic RMI markets continue to be impacted by higher interest rates and weaker consumer confidence driven by persistent, higher than anticipated consumer price inflation," Travis Perkins said.

ITV fell 0.6%. The media company and broadcaster confirmed a Reuters report from Thursday that it is considering an acquisition of production group All3Media. All3Media is jointly owned by Warner Bros Discovery and Liberty Global. According to Reuters sources, ITV is considering combining the business with its Studios unit, and Liberty Global could possibly retain a stake. As well as jointly-owning All3Media, Liberty Global has a roughly 9.9% stake in ITV.

Reuters had previously reported All3Media, which produces Fleabag and Midsomer Murders, could fetch a price tag over GBP1 billion.

On AIM, ValiRx fell 15%

The life sciences company, which focuses on early-stage cancer therapeutics and women's health, said it has concluded its evaluation agreement with Hokkaido University.

"Under this agreement, ValiRx committed to conducting a range of experiments following initial confirmation of the synthetic route and analysis. After overcoming initial challenges in synthesis and purification of the peptide, testing has been conducted on the product," it explained.

The product was subsequently found to be "unsuitable" for further development, and the evaluation will now end.

Still to come on Friday's economic calendar, there's a eurozone inflation reading at 1000 BST.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
21 Feb 2019 12:46

ValiRx Raises GBP500,000 Through Placing To Advance Clinical Trials (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Thursday raised GBP500,000 through a share placing to expand its clinical trial of VAL201, as well as the VAL301 and VAL101 programmes.ValiRx issued a

Read more
31 Jan 2019 13:37

ValiRx Secures Patent For VAL301 Compound In Russia And China

LONDON (Alliance News) - ValiRx PLC on Thursday said it has been granted a patent allowance for its therapeutic compound VAL301 in both Russia and China.The clinical stage biotechnology has

Read more
31 Jan 2019 10:08

ValiRx allowed patents for VAL401 in Russia and China

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced on Thursday that the patent offices of Russia and China had both granted a patent allowance for its pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.

Read more
9 Jan 2019 14:57

ValiRx gives NHS Long Term Plan its seal of approval

(Sharecast News) - Clinical stage biotechnology company ValiRx endorsed the Government's new NHS Long Term Plan to improve the quality of patient care and health outcomes on Wednesday.

Read more
9 Jan 2019 11:25

ValiRx Backs New Long-Term UK Government Plan For NHS

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Wednesday said it endorses the UK government's new NHS long-term plan."The government's recently announced ten-year a

Read more
18 Dec 2018 15:53

VAL401 results accepted for journal publication, says ValiRx

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acceptance for publication of the first article containing results from the VAL401 clinical trial by the European Journal of Drug Metabolism and Pharmacokinetics on Tuesday.

Read more
10 Dec 2018 11:07

ValiRx releases positive data from recent VAL201 testing

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Monday that independent analysis of VAL201 data showed a "statistically significant" dose dependant response in the reduction of PSA correlated to time on the Phase l/ll clinical trial, involving patients with hormone-sensitive and hormone-resistant prostate cancer.

Read more
10 Dec 2018 10:59

WINNERS & LOSERS SUMMARY: Just Group Jumps 23% On Regulatory Decision

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------NMC up The

Read more
10 Dec 2018 09:06

ValiRx Reports Positive VAL201 Effect On Patients With Prostate Cancer

LONDON (Alliance News) - ValiRx PLC on Monday said an independent analysis of VAL201 showed a positive effect on patients with hormone-sensitive and hormone-resistant prostate cancer.The up

Read more
17 Oct 2018 08:36

ValiRx enters finals stages of clinical trials on VAL201

(Sharecast News) - Clinical stage biotechnology company ValiRx's leading anti-cancer therapeutic has entered the concluding stages of its Phase l/ll clinical trial at University College London Hospital.

Read more
25 Sep 2018 13:23

ValiRx Half Year Loss Widens On Expenses And Share Option Charge

LONDON (Alliance News) - Life science company ValiRx PLC on Tuesday reported a widened loss in the first half of 2018 due to expenses and a sizeable share option charge.The company's to

Read more
6 Sep 2018 11:38

ValiRx Says Clinical Study For Lung Cancer Drug VAL401 Is Approved

LONDON (Alliance News) - Clinical stage biotechnology company ValiRx PLC said Thursday its clinical study report on lung cancer drug VAL401 has been signed and approved by principal in ValiRx were

Read more
6 Sep 2018 09:05

ValiRx enters 'very exciting' phase for cancer therapies

(Sharecast News) - ValiRx told investors on Thursday that its clinical-stage therapeutics had continued to demonstrate "significant potential" for addressing unmet medical needs in oncology.

Read more
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
11 May 2018 16:43

Nicholas Slater Increases ValiRx Stake To 4.5% From 2.7% (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday Nicholas Slater had almost doubled his stake in life science company, which focuses on cancer treatments, to 4.5% after a transaction on raised his

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.